• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

析因随机试验的方案内容与报告指南:CONSORT 2010和SPIRIT 2013扩展版的解释与阐述

Guidance for protocol content and reporting of factorial randomised trials: explanation and elaboration of the CONSORT 2010 and SPIRIT 2013 extensions.

作者信息

Kahan Brennan C, Juszczak Edmund, Beller Elaine, Birchenall Megan, Chan An-Wen, Hall Sophie, Little Paul, Fletcher John, Golub Robert M, Goulao Beatriz, Hopewell Sally, Islam Nazrul, Zwarenstein Merrick, Elbourne Diana, Montgomery Alan

机构信息

MRC Clinical Trials Unit at UCL, London WC1V 6LJ, UK

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.

出版信息

BMJ. 2025 Feb 4;388:e080785. doi: 10.1136/bmj-2024-080785.

DOI:10.1136/bmj-2024-080785
PMID:39904527
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11791685/
Abstract

This report presents the explanation and elaboration paper for the CONSORT (Consolidated Standards of Reporting Trials) 2010 and SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 extensions for factorial trials. Factorial trials involve randomising participants to more than one intervention, often with the aim of evaluating multiple interventions in one study or assessing whether treatments interact. The CONSORT and SPIRIT statements have been extended to allow for the unique features of the factorial design. Reporting items along with detailed explanations and examples of good practice are provided, as well as a glossary of key terms and an overview of the methodological features of factorial trials.

摘要

本报告介绍了2010年CONSORT(试验报告统一标准)和2013年SPIRIT(干预性试验标准方案条目:建议)针对析因试验的扩展说明及阐述文件。析因试验涉及将参与者随机分配至一种以上干预措施,其目的通常是在一项研究中评估多种干预措施,或评估治疗方法之间是否存在相互作用。CONSORT和SPIRIT声明已进行扩展,以适应析因设计的独特特征。报告项目以及详细解释和良好实践示例均已提供,同时还提供了关键术语词汇表以及析因试验方法学特征概述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253c/11791685/acadba824768/kahb080785.f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253c/11791685/2420e130cc35/kahb080785.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253c/11791685/acadba824768/kahb080785.f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253c/11791685/2420e130cc35/kahb080785.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253c/11791685/acadba824768/kahb080785.f2.jpg

相似文献

1
Guidance for protocol content and reporting of factorial randomised trials: explanation and elaboration of the CONSORT 2010 and SPIRIT 2013 extensions.析因随机试验的方案内容与报告指南:CONSORT 2010和SPIRIT 2013扩展版的解释与阐述
BMJ. 2025 Feb 4;388:e080785. doi: 10.1136/bmj-2024-080785.
2
Mixed-methods study to develop extensions to the SPIRIT and CONSORT statements for factorial randomised trials: the Reporting Factorial Trials (RAFT) study.一项混合方法研究,旨在为析因随机试验开发SPIRIT和CONSORT声明的扩展内容:析因试验报告(RAFT)研究。
BMJ Open. 2025 Feb 17;15(2):e082917. doi: 10.1136/bmjopen-2023-082917.
3
SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol.早期阶段剂量发现临床试验的 SPIRIT 和 CONSORT 扩展:DEFINE(剂量发现扩展)研究方案。
BMJ Open. 2023 Mar 29;13(3):e068173. doi: 10.1136/bmjopen-2022-068173.
4
Guidelines for reporting pediatric and child health clinical trial protocols and reports: study protocol for SPIRIT-Children and CONSORT-Children.儿科和儿童健康临床试验方案和报告报告指南:SPIRIT-Children 和 CONSORT-Children 的研究方案。
Trials. 2024 Jan 30;25(1):96. doi: 10.1186/s13063-024-07948-7.
5
Improving the completeness and transparency of protocols and reports of randomized trials: SPIRIT 2025 and CONSORT 2025.提高随机试验方案和报告的完整性与透明度:《2025年标准方案项目:干预试验建议(SPIRIT)》及《2025年随机对照试验报告规范(CONSORT)》
J Clin Epidemiol. 2025 Jun;182:111792. doi: 10.1016/j.jclinepi.2025.111792. Epub 2025 Apr 17.
6
SPIRIT 2025 statement: updated guideline for protocols of randomised trials.《SPIRIT 2025声明:随机试验方案的更新指南》
BMJ. 2025 Apr 28;389:e081477. doi: 10.1136/bmj-2024-081477.
7
SPIRIT 2025 statement: Updated guideline for protocols of randomised trials.《SPIRIT 2025声明:随机试验方案的更新指南》
PLoS Med. 2025 Apr 28;22(4):e1004589. doi: 10.1371/journal.pmed.1004589. eCollection 2025 Apr.
8
Recommendations and evidence for reporting items in pediatric clinical trial protocols and reports: two systematic reviews.儿科临床试验方案和报告中报告项目的建议与证据:两项系统评价
Trials. 2015 Sep 18;16:417. doi: 10.1186/s13063-015-0954-0.
9
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols.SPIRIT-DEFINE解释与阐述:提高早期剂量探索性临床试验方案质量与影响力的建议
EClinicalMedicine. 2025 Jan 10;79:102988. doi: 10.1016/j.eclinm.2024.102988. eCollection 2025 Jan.
10
Methods used to develop the SPIRIT 2024 and CONSORT 2024 Statements.用于制定《SPIRIT 2024声明》和《CONSORT 2024声明》的方法。
J Clin Epidemiol. 2024 May;169:111309. doi: 10.1016/j.jclinepi.2024.111309. Epub 2024 Feb 29.

引用本文的文献

1
Realizing the benefits of the estimand framework when reporting and communicating clinical trial results-some recommendations.认识到在报告和交流临床试验结果时使用估计量框架的益处——一些建议。
Trials. 2025 Jul 11;26(1):241. doi: 10.1186/s13063-025-08915-6.
2
Development of a consensus extension of the estimands framework for cluster randomised trials (CRT-estimands): results from an international Delphi study.群组随机试验估计量框架共识扩展(CRT-估计量)的制定:一项国际德尔菲研究的结果
medRxiv. 2025 Jul 3:2025.07.03.25330799. doi: 10.1101/2025.07.03.25330799.

本文引用的文献

1
The estimands framework: a primer on the ICH E9(R1) addendum.估计量框架:ICH E9(R1)增编入门指南。
BMJ. 2024 Jan 23;384:e076316. doi: 10.1136/bmj-2023-076316.
2
Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement.《析因随机临床试验方案的共识声明:SPIRIT 2013 声明的扩展》。
JAMA Netw Open. 2023 Dec 1;6(12):e2346121. doi: 10.1001/jamanetworkopen.2023.46121.
3
Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement.报告析因随机试验:CONSORT 2010 声明的扩展。
JAMA. 2023 Dec 5;330(21):2106-2114. doi: 10.1001/jama.2023.19793.
4
When should factorial designs be used for late-phase randomised controlled trials?何时应使用析因设计进行后期随机对照试验?
Clin Trials. 2024 Apr;21(2):162-170. doi: 10.1177/17407745231206261. Epub 2023 Oct 31.
5
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance.提高早期剂量发现临床试验的报告质量和影响力:CONSORT 剂量发现扩展(CONSORT-DEFINE)指南。
BMJ. 2023 Oct 20;383:e076387. doi: 10.1136/bmj-2023-076387.
6
Design and analysis of factorial clinical trials: The impact of one treatment's effectiveness on the statistical power and required sample size of the other.析因临床试验的设计与分析:一种治疗方法效果对另一种方法的统计功效和所需样本量的影响。
Stat Methods Med Res. 2023 Jun;32(6):1124-1144. doi: 10.1177/09622802231163332. Epub 2023 Apr 19.
7
Eliminating Ambiguous Treatment Effects Using Estimands.利用目标治疗估计值消除模糊的治疗效果。
Am J Epidemiol. 2023 Jun 2;192(6):987-994. doi: 10.1093/aje/kwad036.
8
Assessment of infant position and timing of stylet removal to improve lumbar puncture success in neonates (NeoCLEAR): an open-label, 2 × 2 factorial, randomised, controlled trial.评估婴儿体位及拔出针芯时机以提高新生儿腰椎穿刺成功率(NeoCLEAR):一项开放标签、2×2析因、随机对照试验。
Lancet Child Adolesc Health. 2023 Feb;7(2):91-100. doi: 10.1016/S2352-4642(22)00343-1. Epub 2022 Nov 29.
9
Evaluating how clear the questions being investigated in randomised trials are: systematic review of estimands.评估随机试验中所调查问题的清晰度:估计量的系统评价。
BMJ. 2022 Aug 23;378:e070146. doi: 10.1136/bmj-2022-070146.
10
EvaLuation of early CRRT and beta-blocker InTervention in patients with ECMO (ELITE) trial: study protocol for a 2 × 2 partial factorial randomized controlled trial.ECMO 患者早期 CRRT 和β受体阻滞剂干预的评估(ELITE)试验:一项 2×2 部分析因随机对照试验的研究方案。
Trials. 2022 Aug 19;23(1):684. doi: 10.1186/s13063-022-06617-x.